UK body blocks earlier use of J&J prostate cancer drug

May 13, 2014 11:36 PM

11 0

LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE said on Wednesday that a Johnson & Johnson prostate cancer drug, originally invented in Britain, was not worth giving to patients who have yet to receive chemotherapy.

Although Zytiga, or abiraterone, is already cleared for use in some men after chemotherapy, a green light for its earlier use would allow many more patients to access the oral medicine.

Read more

To category page